Search

Displaying results 2841 - 2850 of 10000 in total
  1. Drug

    Thyroglobulin

    go.drugbank.com/drugs/DB01584
    ApprovedWithdrawn

    Thyroglobulin (also known as Tg) is an enzyme thyroid hormone used by the thyroid gland to produce the thyroid hormones thyroxine (T4) and triiodothyronine (T3).

  2. Drug

    Foreskin keratinocyte (neonatal)

    go.drugbank.com/drugs/DB10772
    Approved

    The defining moment in skin culture was in 1975 when Rheinwald and Green successfully grew human keratinocytes on lethally irradiated murine fibroblasts. … Foreskin keratinocytes are an important ingredient in several skin substitutes [L2460], used for various indications.

  3. Drug

    Thymidine

    go.drugbank.com/drugs/DB04485
    ApprovedInvestigational

    toxicity of established anti-metabolite chemotherapeutic agents, such as 5-Fluorouracil (FU), Methotrexate (MTX), and Cytosine arabinoside (ara-C). … [A274683, A274688] As of now, its primary role is in research and as a sensitizer or modulator in experimental chemotherapy regimens, rather than a standalone, approved therapeutic agent.

    Synonyms: MT-1621 COMPONENT 2'-DEOXYTHYMIDINE, -D-erythro-pentofuranosyl)-5-methyl-
  4. Drug

    Fenfluramine

    go.drugbank.com/drugs/DB00574
    ApprovedIllicitInvestigationalWithdrawn

    [A214688, A214691, A214700] Fenfluramine was granted initial FDA approval in 1973 prior to its withdrawal; it was granted a new FDA approval on June 25, 2020, for treatment of patients with Dravet syndrome … from the market in 1997.

    Synonyms: DL-Fenfluramine, 1-(m-trifluoromethyl-phenyl)-2-ethylaminopropane
  5. Drug

    Emapalumab

    go.drugbank.com/drugs/DB14724
    ApprovedInvestigational

    Emapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018.

  6. Drug

    Seletracetam

    go.drugbank.com/drugs/DB05885
    Investigational

    As of 2010, its production was further halted due to the investigation of a newer antiepileptic agent, brivaracetam. … Food and Drug Administration (FDA) investigated as treatment of epilepsy and partial epilepsy however its development had been put on hold in July 2007.

  7. Drug

    Phenyltoloxamine

    go.drugbank.com/drugs/DB11160
    Approved

    Nevertheless, phenyltoloxamine is used to a fairly limited extent in contemporary medicine, with only very few products involving it as an active ingredient. … Phenyltoloxamine citrate is the more common salt form that acts as an active ingredient in pharmaceutical products and promotes hay fever relief via reversing the effects of histamine.

    Mixtures: Dologesic DF
  8. Drug

    Icotrokinra

    go.drugbank.com/drugs/DB21724
    ApprovedInvestigational

    Icotrokinra is a first-in-class, targeted oral peptide and interleukin-23 (IL-23) receptor antagonist. … [L56108,L56118] Icotrokinra was approved by the US FDA in March 2026 for the systemic treatment of moderate-to-severe plaque psoriasis.[L56108]

  9. Drug

    Nedosiran

    go.drugbank.com/drugs/DB17635
    ApprovedInvestigational

    [A261685] Nedosiran was approved by the FDA on October 2<sup>nd</sup>, 2023, under the brand name RIVFLOZA to lower urinary oxalate levels in children 9 years of age and older and adults with primary … Nedosiran is an RNA interference targeting hepatic lactate dehydrogenase, the enzyme responsible for the conversion of glyoxylate to oxalate.

  10. Drug

    Molnupiravir

    go.drugbank.com/drugs/DB15661
    Investigational

    Molnupiravir (EIDD-2801, MK-4482) is the isopropylester prodrug of [N4-hydroxycytidine]. … [A193014] Molnupiravir was granted approval by the UK's Medicines and Health products Regulatory Agency (MHRA) on 4 November 2021 to prevent severe outcomes such as hospitalization and death due to